COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The Company is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.
ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.